CGH
MRNA icon

Crossmark Global Holdings’s Moderna MRNA Stock Holding History

Crossmark Global Holdings’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.37M Buy
19,587
+661
+3% +$34.2K 0.02% 553
2026
Q1 		$961K Sell
18,926
-1,835
-9% -$85.6K 0.01% 618
2025
Q4 		$612K Buy
20,761
+7,768
+60% +$211K 0.01% 763
2025
Q3 		$336K Sell
12,993
-126
-1% -$3.52K 0.01% 1054
2025
Q2 		$362K Sell
13,119
-603
-4% -$15.9K 0.01% 1021
2025
Q1 		$389K Sell
13,722
-195
-1% -$6.92K 0.01% 972
2024
Q4 		$579K Hold
13,917
– – 0.01% 772
2024
Q3 		$930K Sell
13,917
-115
-0.8% -$10.6K 0.02% 637
2024
Q2 		$1.67M Sell
14,032
-265
-2% -$33.5K 0.03% 448
2024
Q1 		$1.52M Sell
14,297
-227
-2% -$22.9K 0.03% 491
2023
Q4 		$1.44M Sell
14,524
-273
-2% -$23K 0.03% 490
2023
Q3 		$1.55M Sell
14,797
-248
-2% -$27.7K 0.04% 456
2023
Q2 		$1.78M Buy
15,045
+190
+1% +$25.3K 0.04% 443
2023
Q1 		$2.28M Sell
14,855
-629
-4% -$104K 0.05% 370
2022
Q4 		$2.78M Buy
15,484
+707
+5% +$116K 0.07% 308
2022
Q3 		$1.75M Buy
14,777
+194
+1% +$29.4K 0.05% 392
2022
Q2 		$2.08M Sell
14,583
-740
-5% -$106K 0.05% 372
2022
Q1 		$2.64M Sell
15,323
-1,280
-8% -$215K 0.06% 327
2021
Q4 		$4.22M Buy
16,603
+730
+5% +$213K 0.09% 226
2021
Q3 		$6.11M Buy
15,873
+13,820
+673% +$5.1M 0.14% 165
2021
Q2 		$482K Sell
2,053
-20
-1% -$3.57K 0.01% 949
2021
Q1 		$271K Buy
2,073
+10
+0.5% +$1.45K 0.01% 1225
2020
Q4 		$216K Buy
+2,063
New +$209K 0.01% 1274

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Crossmark Global Holdings's MRNA Position: Q2 2026 in Review

Crossmark Global Holdings increased its Moderna (MRNA) stake by 3.5% in Q2 2026, buying an estimated $34.2K and bringing the position to 19,587 shares worth $1.37M. The position accounts for 0.02% of the portfolio, ranked #553.

Crossmark Global Holdings first reported a position in MRNA in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.11M in Q3 2021. 777 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

  • Crossmark Global Holdings held 19,587 shares of Moderna worth $1.37M as of Q2 2026.
  • Crossmark Global Holdings bought 661 Moderna shares in Q2 2026, an estimated $34.2K.
  • Moderna made up 0.02% of Crossmark Global Holdings's portfolio in Q2 2026, its #553 holding.
  • Crossmark Global Holdings first reported a position in Moderna in Q4 2020 and has held it in 23 quarters since.
  • Crossmark Global Holdings's Moderna position peaked at $6.11M in Q3 2021.
  • 777 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.